Gastrointestinal and Hepatic Manifestations of Chronic Granulomatous Disease.
Abscess
CGD
IBD
Motility
Portal hypertension
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
08
07
2022
revised:
02
12
2022
accepted:
20
12
2022
medline:
9
5
2023
pubmed:
17
1
2023
entrez:
16
1
2023
Statut:
ppublish
Résumé
Chronic granulomatous disease (CGD) is a rare inborn error of immunity, resulting from a defect in nicotinamide adenine dinucleotide phosphate oxidation and decreased production of phagocyte reactive oxygen species. The main clinical manifestations are recurrent infections and chronic inflammatory disorders. Current approaches to management include antimicrobial prophylaxis and control of inflammatory complications. Hematopoietic stem cell transplantation or gene therapy can provide definitive treatment. Gastrointestinal and hepatic manifestations are common in CGD and include structural changes, dysmotility, CGD-associated inflammatory bowel disease, liver abscesses, and noncirrhotic portal hypertension. The findings can be heterogeneous, and the management is complex in light of the underlying immune dysfunction. This review describes the various clinical findings and the latest studies in management of gastrointestinal and hepatic manifestations in CGD, as well as the management experience at the National Institutes of Health.
Identifiants
pubmed: 36646382
pii: S2213-2198(23)00050-8
doi: 10.1016/j.jaip.2022.12.039
pii:
doi:
Substances chimiques
NADPH Oxidases
EC 1.6.3.-
Types de publication
Review
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1401-1416Informations de copyright
Published by Elsevier Inc.